Home > Name List By other > (3R, 5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2- ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Canada

CAS No 134523-00-5 , (3R,
5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-
ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Search by region : Canada

  • Name: (3R,
    5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-
    ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
  • Synonyms: Torvast; Sotis; Lipotropic; Faboxim;Cardyl;(3R,
    5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-
    ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Tozalip; Lipitor; Atorpic; Xavator;
  • CAS Registry Number:
  • Density: 1.23 g/cm3
  • Safety Statements: S26;S36;
  • Hazard Symbols: Xn
  • Molecular Weight: 558.639803
  • InchiKey: XUKUURHRXDUEBC-KAYWLYCHSA-N
  • InChI: InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-
    3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28
    (39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,
    27-/m1/s1
  • Risk Statements: 20/21/22-36/37/38
  • Molecular Formula: C33H35FN2O5
  • Molecular Structure:CAS No:134523-00-5 (3R,<br />5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-<br />ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid

Related products

Select to

134523-00-5 Atorvastatin calcium salt

  • Atorvastatin calcium salt
  • Canada SynFine Research Inc. [Manufacturer]
  • Tel: 905-737-2702
  • Fax: 905-737-6299
  • Address: SynFine Research Inc.
    P.O. Box 433 ? Station A
    Richmond Hill, ON L4C 4Y8
    Canada null,nullCanada
Contact Supplier

Select to

1/1
References of (3R,
5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-
ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
Title: Atorvastatin
CAS Registry Number: 134523-00-5
CAS Name: (bR,dR)-2-(4-Fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
Molecular Formula: C33H35FN2O5
Molecular Weight: 558.64
Percent Composition: C 70.95%, H 6.31%, F 3.40%, N 5.01%, O 14.32%
Literature References: HMG-CoA reductase inhibitor. Prepn: B. D. Roth, EP 409281; idem, US 5273995 (1991, 1993 both to Warner-Lambert); K. L. Baumann et al., Tetrahedron Lett. 33, 2283 (1992). Solubility and kinetic studies: A. S. Kearney et al., Pharm. Res. 10, 1461 (1993). LC/MS/MS determn in serum: M. Jemal et al., Rapid Commun. Mass Spectrom. 13, 1003 (1999). Clinical pharmacokinetics: D. D. Cilla, Jr. et al., Clin. Pharmacol. Ther. 60, 687 (1996). Review of pharmacology and clinical experience: H. S. Yee, N. T. Fong, Ann. Pharmacother. 32, 1030-1043 (1998); of efficacy in diabetic patients: K. F. Croom, G. L. Plosker, Drugs 65, 137-152 (2005).
 
Derivative Type: Calcium salt trihydrate
CAS Registry Number: 344423-98-9; 134523-03-8 (anhydrous)
Manufacturers' Codes: CI-981
Trademarks: Lipitor (Parke-Davis); Sortis (Pfizer); Torvast (Pfizer); Totalip (Guidotti)
Molecular Formula: C66H68CaF2N4O10.3H2O
Molecular Weight: 1209.39
Percent Composition: C 65.55%, H 6.17%, Ca 3.31%, F 3.14%, N 4.63%, O 17.20%
Properties: White to off-white crystalline powder. [a]D -7.4° (c = 1 in DMSO). Freely sol in methanol; slightly sol in ethanol; very slightly sol in acetonitrile, distilled water, phosphate buffer (pH 7.4). Insol in aq solns of pH 4 and below.
Optical Rotation: [a]D -7.4° (c = 1 in DMSO)
 
Derivative Type: Sodium salt
CAS Registry Number: 134523-01-6
Molecular Formula: C33H34FN2NaO5
Molecular Weight: 580.62
Percent Composition: C 68.26%, H 5.90%, F 3.27%, N 4.82%, Na 3.96%, O 13.78%
Properties: pKa 4.46. Soly in water (30°): 20.4 mg/ml (pH 2.1); 1.23 mg/ml (pH 6.0).
pKa: pKa 4.46
 
Derivative Type: Lactone
CAS Registry Number: 125995-03-1
CAS Name: 5-(4-Fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxamide
Molecular Formula: C33H33FN2O4
Molecular Weight: 540.62
Percent Composition: C 73.31%, H 6.15%, F 3.51%, N 5.18%, O 11.84%
Properties: mp 159.2-160.7°. [a]D +26.05° (c = 1 in chloroform).
Melting point: mp 159.2-160.7°
Optical Rotation: [a]D +26.05° (c = 1 in chloroform)
 
Therap-Cat: Antilipemic.
Keywords: Antilipemic; HMG CoA Reductase Inhibitors; HMG CoA Reductase Inhibitor.